Loading...

Medexus Pharmaceuticals Inc.

MDP.TOTSX
Healthcare
Drug Manufacturers - Specialty & Generic
CA$2.66
CA$-0.08(-2.92%)

Medexus Pharmaceuticals Inc. (MDP.TO) Company Profile & Overview

Explore Medexus Pharmaceuticals Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Medexus Pharmaceuticals Inc. (MDP.TO) Company Profile & Overview

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOKenneth d'Entremont

Contact Information

877 633 3987
35 Nixon Road, Bolton, ON, L7E 1K1

Company Facts

82 Employees
IPO DateJan 9, 2014
CountryCA
Actively Trading

Frequently Asked Questions

;